MicuRx Pharmaceuticals has begun a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The Phase II double-blind, multi-center, active comparator-controlled clinical study will enroll more than 200 patients with complicated skin and skin structure infections in China. MicuRx is also enrolling volunteers i...